Long-Term Follow-Up of a Patient with Primary Presacral Neuroendocrine Tumor: A Case Report with Literature Review

Mi Ra Kim
Hye-kyung Shim

Corresponding Author: Hye-kyung Shim, e-mail: shimhk80@naver.com
Conflict of interest: None declared

Patient: Male, 78-year-old
Final Diagnosis: Presacral neuroendocrine tumors
Symptoms: Asymptomatic
Medication: —
Clinical Procedure: Peptide receptor radionuclide therapy
Specialty: Nuclear Medicine

Objective: Rare disease
Background: Primary neuroendocrine tumors (NETs) in the retroperitoneal space are extremely rare. We report the case of a patient diagnosed with primary presacral NET in the retroperitoneum that was initially suspected to be hepatic metastasis, who was followed up for more than 8 years.

Case Report: A 78-year-old man was referred to our hospital for the treatment of a hepatic mass. Following resection, the patient was diagnosed with a grade 2 well-differentiated NET. A thorough evaluation to identify the primary tumor detected small well-demarcated presacral nodules on In-111 octreotide single-photon emission tomography/computed tomography (SPECT/CT). Metastases to other locations were not observed. Presacral nodules were difficult to remove using the surgical approach; therefore, we decided to follow up closely. After 4 years, the patient was diagnosed with recurrent hepatic metastasis and peritoneal seeding. Although combination therapy of everolimus and octreotide long-acting repeatable was administered, it was discontinued owing to disease progression. Baseline Ga-68 DOTATOC positron emission tomography-computed tomography revealed adequate avidity for the lesions observed on SPECT/CT; therefore, 5 cycles of peptide receptor radionuclide therapy (PRRT) were administered, after which stable disease was maintained.

Conclusions: We identified an extremely rare primary retroperitoneal NET on In-111 octreotide SPECT/CT. During long-term follow-up, although the patient presented with recurrent hepatic metastases and peritoneal seeding, PRRT was successful in stabilizing the disease.

MeSH Keywords: Diagnostic Techniques, Radioisotope • Neuroendocrine Tumors • Positron-Emission Tomography • Radionuclide Imaging • Retroperitoneal Neoplasms • Tomography, Emission-Computed, Single-Photon
Background

Neuroendocrine tumors (NETs) are a heterogeneous group of malignant tumors arising from enterochromaffin cells, with varying clinical manifestations. NETs can occur in almost any organ, but are mainly observed in the gastroenteropancreatic system (70%), respiratory system (25%), and other primary sites (5%) [1]. As primary NETs in the retroperitoneal space are extremely rare, preoperative diagnosis is very difficult because of the indolent tumor characteristics and complex anatomy of the location in which the tumors occur [2]. Presacral well-differentiated NETs (WDNETs) in the retroperitoneum can occur directly or owing to metastasis from rectal carcinoids [2] or from primary presacral neoplasms. Small primary NETs are known to cause large hepatic metastases [3,4]. However, metastatic NETs are often observed in the liver, because the entire systemic blood supply passes through the liver, making it a prime target for metastatic disease [5].

The 2017 World Health Organization (WHO) classification divides neuroendocrine neoplasms (NENs) into 2 different groups: well-differentiated, low-proliferating NENs such as NETs or carcinoids; and poorly differentiated, highly proliferating NENs such as small- or large-cell neuroendocrine carcinomas (NECs) [1,6]. This classification, which is critical for assessing the tumor grade and the possible disease prognosis [7], is based on the histologic grade of the tumor considering the mitotic count and Ki-67 labeling index. When the Ki-67 index is low (<3%) and the mitotic count is <2 per 10 high-power fields (HPFs), the tumor is classified as a G1 NET. For G2 NETs, the Ki-67 index is 3–20% and the mitotic count is 2–20 per 10 HPFs. G3 NETs have a Ki-67 index >20% and a mitotic count of >20 per 10 HPFs [6]. The staging system for NENs has not yet been well-established. Herein, on the basis of this classification, we report a case of a G2 WDNET with hepatic metastasis arising from the presacral space, along with a literature review.

Case Report

A 78-year-old man was referred to our hospital for treatment of a left liver mass that was suspected to be a carcinoma, mostly hepatocellular carcinoma, after histological examination at another hospital. He was undergoing treatment for diabetes, which was well controlled, and had no history of smoking or consumption of alcohol. He also had no history of liver disease, including hepatitis and cirrhosis. Physical examination findings were unremarkable. The results of laboratory tests were within normal limits, including the levels of tumor markers such as alpha-fetoprotein, carbohydrate antigen 19-9, protein induced by vitamin K absence or antagonist II, and carcinoembryonic antigen. Abdominopelvic computed tomography (APCT) and

Figure 1. (A) Axial In-111 octreotide SPECT/CT findings. There were 2 well-demarcated small round nodules with In-111 octreotide uptake in the presacral area on 24-h In-111 octreotide scans. (B) Anterior-posterior whole-body In-111 octreotide scan findings. There were no other abnormal In-111 octreotide-avid lesions in the rest of the body. Normal physiologic uptake was noted in the liver, spleen, kidneys, bowels, and bladder. (C) Coronal abdominopelvic enhanced computed tomography findings. Heterogeneously enhanced nodules of 2.1×1.7 cm and 1.0×0.9 cm (solid black arrow) were noted abutting the left internal iliac vessels and presacral fascia (white dotted arrow).
gadolinium-enhanced magnetic resonance (MRI) scans revealed a round heterogeneous mass measuring 3 cm in the left lobe of the liver. The patient underwent laparoscopic left lateral sectionectomy. On histopathologic examination, tumor cells with abundant cytoplasm and vesicular nuclei chromatin were observed in a trabecular pattern. Immunohistochemical (IHC) staining and molecular studies of tumor cells revealed focal positivity for chromogranin, synaptophysin, and CD56. The mitotic count was 8 per 10 HPFs and the Ki-67 index was 6.6%. Thus, according to the 2017 WHO classification, the tumor was diagnosed as a G2 WDNET. Comprehensive tests were then performed to determine the primary site and the differential diagnosis of metastatic NETs. IHC staining revealed negative results for cytokeratin 7 (CK-7), thyroid transcription factor-1 (TTF-1), and CDX2. Chest CT, F-18 fludeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), gastroduodenoscopy, and colonoscopy were unable to determine the primary tumor site; however, In-111 octreotide scans revealed 2 octreotide-avid nodules in the left side of the presacral retroperitoneum (Figure 1A, 1B).

Corresponding heterogeneously enhanced nodules measuring 2.1×1.7 cm and 1.0×0.9 cm were observed in the presacral area on APCT (Figure 1C). No other metastases were found, and the presacral nodules were difficult to consider for surgery; hence, we decided to follow up closely. Approximately 4 years later, there was no significant change in the presacral lesions, but multiple new lesions were observed in the liver (Figure 2A, 2B). Ultrasound-guided biopsy was performed for the new lesions in the liver, which were subsequently diagnosed as G2 WDNETs. Peritoneal seeding was confirmed on the follow-up In-111 octreotide scan (Figure 2C). Metastatic NETs including hepatic and peritoneal seeding worsened and were accompanied by intractable diarrhea. The advanced and metastatic NETs were treated using a combination therapy of octreotide long-acting repeatable (LAR) repeatedly administered intramuscularly at a dose of 20 mg and everolimus 10 mg/day, which is an oral mammalian target of rapamycin (mTOR) inhibitor. Everolimus was administered for 6 weeks, but treatment was discontinued owing to the occurrence of grade 3 stomatitis. Although a transient treatment response was observed after octreotide
LAR treatment for 10 months and everolimus re-treatment for 8 weeks, the presacral mass and metastatic lesions in the liver and peritoneum showed progression on radiologic examinations. Therefore, NETs were considered to be refractory to the combination treatment with octreotide LAR and everolimus, and the treatment was discontinued. Owing to the failure of other systemic treatments, the progressive NETs were treated with pazopanib (800 mg/day, an oral multi-kinase inhibitor). Baseline Ga-68 DOTATOC PET-CT was performed before the scheduled peptide receptor radionuclide therapy (PRRT) at another hospital because PRRT is not approved in Korea (Figure 3). After 5 cycles of 8.0 GBq PRRT, Lu-177 DOTATATE performed after an 8-week interval revealed that the presacral and metastatic lesions showed no significant changes (Figure 4A, 4B). The patient was then closely followed up.

Discussion

This is a report of a rare primary retroperitoneal NET that initially presented as a hepatic mass that was otherwise missed on conventional imaging modalities. The presacral region in the retroperitoneum is usually a potential space and is clinically important; it is composed of complex anatomical structures,
such as the axial muscles, lumbosacral nerve trunk, sacral plexus, iliac vessels, and pelvic soft tissues, as well as multiple embryological remnants [8].

The diagnosis and identification of primary hepatic NETs are difficult and controversial because of the following reasons. (1) The liver does not contain neuroendocrine cells. (2) Metastasis to the liver is the most common, irrespective of the NET grade and it is synchronous with other metastases in 45–95% of cases [7]; in addition, small primary NETs are known to cause large metastases in the liver [5]. (3) There have been no morphologic or IHC markers to definitely rule out the extra-hepatic origin [5]. (4) A thorough examination of other suspected primary sites is needed to confirm the primary site of metastases to the liver. Histopathological examinations including IHC (e.g., chromogranin A, synaptophysin, and CD56) are important for diagnosing NETs. In our case, IHC staining was performed to identify primary sites, and hepatic metastatic NETs were negative for TTF-1 (a marker for a differentiated metastatic tumor originating from the foregut NET), CK-7 (a marker for cholangiocarcinoma), and CDX2 (a highly sensitive and specific marker for adenocarcinomas of intestinal origin) [8]. No lesions were suspected to be primary NET from the stomach to the rectum on endoscopic evaluation.

Imaging studies play an essential role in the detection and localization of primary and/or metastatic NETs [9]. CT and/or MRI have excellent sensitivity and detection rates, both of which are approximately 80% (76–100% for CT and 67–100% for MRI), because primary and metastatic NETs are usually well enhanced after the intravenous injection of contrast agents [9]. In addition, CT is useful for the detection of primary site tumors when the location of the primary NETs is unknown, and MRI easily reveals hepatic metastasis of NETs and primary pancreatic NETs [9]. Our patient also showed no abnormal lesions on APCT and no definite space-occupying lesion in the
Toms of carcinoid syndrome, such as flushing, sweating, and constipation [8]. Presacral NETs usually do not cause symptoms associated with their mass effect, such as low back pain and constipation [8]. Presacral NETs usually do not cause symptoms of carcinoid syndrome, such as flushing, sweating, and hypertension; however, in the current case, the patient developed intractable diarrhea, which indicates carcinoid syndrome, usually observed in patients with advanced and metastatic NETs. The first-line systemic treatment for patients with advanced or metastatic NETs is usually a combination of SSAs for controlling the tumor growth and hormonal secretion, and everolimus [15–17]. The combination therapy of SSAs and mTOR inhibitors can improve the progression-free survival (PFS) but not the overall survival [15]. Pazopanib is an oral multi-kinase inhibitor that is a treatment option for advanced and metastatic NETs because it increases the PFS of patients who did not respond to other systemic treatments including mTOR inhibitors and other multitargeted agents [18].

PRRT is another treatment modality that includes the use of radiolabeled SSAs for patients with advanced or metastatic NETs refractory to octreotide LAR treatment. It is associated with markedly longer PFS and better clinical outcomes [16,17]. Lu-177 is a β-emitter that has a higher range and energy than other radionuclides as well as higher emission of γ-rays, thereby making it useful for monitoring tumor response. Lu-177 DOTATATE results in a significantly higher response rate and an improvement in the quality of life, with a 79% reduction in the risk of progression or death [11,17]. In our patient, stable disease was maintained after administering 5 cycles of PRRT.

**Conclusions**

Clinicians and radiologists need to consider the diagnostic difficulty associated with small and asymptomatic primary presacral NETs, as well as its rarity. Our patient initially presented with a hepatic mass; however, using In-111 octreotide SPECT/CT, we successfully diagnosed small primary presacral NETs, as well as its rarity. Our patient initially presented with a hepatic mass; however, using In-111 octreotide SPECT/CT, we successfully diagnosed small primary presacral NETs, which was otherwise missed on conventional imaging modalities. During the long-term follow-up, although the disease progressed with recurrent hepatic metastases and peritoneal seeding refractory to the systemic treatment, stable disease was maintained through PRRT. As shown in this case, the long-term progressive clinical course of presacral NETs could help understand these rare diseases.

**Ethics approval**

This study was conducted in compliance with the Institutional Review Board (IRB) regulations (approval ID: HPIRB 2019-09-003) and the Declaration of Helsinki.

**Conflict of interest**

None.
